id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6017-0007,FDA,FDA-2017-E-6017,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:24:01Z,,0,0,0900006483f86b42
FDA-2017-E-6017-0006,FDA,FDA-2017-E-6017,"Determination of Regulatory Review Period for Purposes of Patent
Extension; PARSABIV",Notice,Determinations,2018-12-31T05:00:00Z,2018,12,2018-12-31T05:00:00Z,2019-02-27T04:59:59Z,2018-12-31T23:00:56Z,2018-28221,0,0,09000064839d2141
FDA-2017-E-6017-0005,FDA,FDA-2017-E-6017,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:45:32Z,,0,0,09000064839c06af
FDA-2017-E-6017-0004,FDA,FDA-2017-E-6017,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T15:32:54Z,,0,0,090000648378b875
FDA-2017-E-6017-0003,FDA,FDA-2017-E-6017,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T20:15:10Z,,0,0,0900006482bd61b9
FDA-2017-E-6017-0001,FDA,FDA-2017-E-6017,Patent Extension Application from McDermott Will & Emerly LLP (on behalf of KAI Pharmaceuticals Inc),Other,Application,2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T13:33:04Z,,0,0,0900006482b98c1b
FDA-2017-E-6017-0002,FDA,FDA-2017-E-6017,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T13:40:38Z,,0,0,0900006482b9b03d